PharmaEssentia (6446) Q4 2025 earnings summary

Executive summary

• Consolidated revenue reached NTD 15,634,777 thousand in 2025, up 61% year-over-year, driven mainly by medicine product sales in the U.S. market.

• Net income for 2025 was NTD 5,045,167 thousand, a 70% increase compared to 2024.

• Gross margin improved to 89% in 2025 from 88% in 2024.

• The company resolved to invest USD 46 million in a new manufacturing facility in Puerto Rico to expand U.S. supply chain capacity.

Financial highlights

• Operating revenue: NTD 15,634,777 thousand in 2025 vs. NTD 9,734,814 thousand in 2024.

• Net income: NTD 5,045,167 thousand in 2025 vs. NTD 2,965,503 thousand in 2024.

• Basic EPS: NTD 13.64 in 2025 vs. NTD 8.06 in 2024.

• Cash and cash equivalents: NTD 22,692,972 thousand as of Dec 31, 2025.

• Total assets: NTD 37,411,294 thousand as of Dec 31, 2025.

Outlook and guidance

• The company plans to enhance production capacity and strengthen its U.S. market supply chain with a new Puerto Rico facility.

• Ongoing investments in clinical trials and R&D for new indications and geographies.